Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lifted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 663.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,345 shares of the biopharmaceutical company's stock after purchasing an additional 4,645 shares during the quarter. Los Angeles Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $4,694,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 0.5% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 8,391 shares of the biopharmaceutical company's stock worth $6,905,000 after purchasing an additional 42 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in shares of Regeneron Pharmaceuticals by 29.4% during the third quarter. Stratos Wealth Partners LTD. now owns 466 shares of the biopharmaceutical company's stock valued at $383,000 after acquiring an additional 106 shares during the last quarter. Everhart Financial Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 13.1% in the third quarter. Everhart Financial Group Inc. now owns 388 shares of the biopharmaceutical company's stock valued at $319,000 after acquiring an additional 45 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.7% in the third quarter. Lindbrook Capital LLC now owns 1,030 shares of the biopharmaceutical company's stock worth $848,000 after acquiring an additional 37 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 8.6% in the third quarter. GPS Wealth Strategies Group LLC now owns 443 shares of the biopharmaceutical company's stock worth $365,000 after acquiring an additional 35 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company's stock, valued at $17,953,838.10. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,095 shares of company stock valued at $8,729,766. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Up 0.2 %

NASDAQ REGN traded up $1.64 on Monday, reaching $958.64. The stock had a trading volume of 351,998 shares, compared to its average volume of 498,218. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The stock has a fifty day moving average price of $943.14 and a two-hundred day moving average price of $898.30. The firm has a market capitalization of $105.22 billion, a price-to-earnings ratio of 28.32, a P/E/G ratio of 2.74 and a beta of 0.17. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Regeneron Pharmaceuticals's revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company earned $10.96 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on REGN shares. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, April 30th. UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a "buy" rating in a research note on Wednesday, April 17th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 13th. Cantor Fitzgerald restated a "neutral" rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday. Finally, Truist Financial reiterated a "buy" rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $981.71.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.